PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8

Animals Breast Neoplasms / drug therapy CD40 Antigens / metabolism CD8-Positive T-Lymphocytes Cross-Priming Dendritic Cells Female Humans Immunity, Innate Mice Tumor Microenvironment
CD40 Cross-presentation DC MDSC PKC

Journal

Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053

Informations de publication

Date de publication:
10 04 2022
Historique:
received: 21 10 2021
revised: 01 01 2022
accepted: 13 01 2022
pubmed: 26 1 2022
medline: 23 4 2022
entrez: 25 1 2022
Statut: ppublish

Résumé

Myeloid-derived suppressor cells (MDSCs) are an immature innate cell population that expands in pathological conditions such as cancer and suppresses T cells via production of immunosuppressive factors. Conversely, efficient cytotoxic T cell priming is dependent on the ability of antigen-presenting cells (APCs) to cross-present tumor antigens to CD8

Identifiants

DOI: 10.1016/j.canlet.2022.01.017 PMID: 35074498 PMC: PMC9867936
pubmed: 35074498
pii: S0304-3835(22)00025-8
doi: 10.1016/j.canlet.2022.01.017
pmc: PMC9867936
mid: NIHMS1857097
pii:
doi:

Substances chimiques

CD40 Antigens 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

98-108

Subventions

Organisme : NCI NIH HHS
ID : F32 CA250192
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA253329
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA262112
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA226969
Pays : United States
Organisme : NCI NIH HHS
ID : F31 CA268871
Pays : United States

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Références

Cancer Res. 2016 May 1;76(9):2698-709
pubmed: 26984756
Lab Anim (NY). 2013 Jun;42(6):217-24
pubmed: 23689461
Blood. 2005 Aug 15;106(4):1362-8
pubmed: 15845901
J Immunol. 2019 Feb 15;202(4):1265-1286
pubmed: 30659108
Nat Rev Immunol. 2014 Aug;14(8):571-8
pubmed: 25033907
Cell Mol Immunol. 2018 Mar;15(3):246-259
pubmed: 27867197
Toxins (Basel). 2010 Jan;2(1):174-94
pubmed: 22069553
Br J Haematol. 2009 Jun;145(6):761-74
pubmed: 19388934
Trends Cancer. 2018 Nov;4(11):784-792
pubmed: 30352680
Trends Immunol. 2016 Mar;37(3):208-220
pubmed: 26858199
Immunity. 2016 Apr 19;44(4):924-38
pubmed: 27096321
Nat Commun. 2019 Sep 27;10(1):4401
pubmed: 31562311
Immunol Res. 1997 Feb;16(1):59-70
pubmed: 9048208
Cancer Res. 2004 Apr 15;64(8):2833-9
pubmed: 15087400
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
J Exp Med. 2021 Apr 5;218(4):
pubmed: 33755718
Nat Rev Cancer. 2007 Apr;7(4):281-94
pubmed: 17384583
Front Immunol. 2013 Dec 11;4:438
pubmed: 24376443
Nature. 2020 Mar;579(7798):284-290
pubmed: 32103175
Front Cell Dev Biol. 2020 May 19;8:351
pubmed: 32509781
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
Trends Pharmacol Sci. 2017 May;38(5):438-447
pubmed: 28283201
Int Immunol. 2007 Jul;19(7):813-24
pubmed: 17606980
Immunol Rev. 2008 Aug;224:141-65
pubmed: 18759925
J Clin Invest. 2015 Sep;125(9):3365-76
pubmed: 26325033
Nat Cell Biol. 2016 Oct;18(10):1065-77
pubmed: 27617930
Annu Rev Immunol. 2013;31:563-604
pubmed: 23516985
Cell. 2018 Feb 8;172(4):825-840.e18
pubmed: 29336888
Oncologist. 2020 Mar;25(3):e423-e438
pubmed: 32162802
Nat Rev Immunol. 2021 Aug;21(8):485-498
pubmed: 33526920
Cell Rep. 2021 Jun 22;35(12):109285
pubmed: 34161764
Nat Immunol. 2002 Jan;3(1):69-75
pubmed: 11743587
Cancer Lett. 2015 Jan 28;356(2 Pt B):686-96
pubmed: 25449427
Pharmacol Res. 2007 Jun;55(6):461-6
pubmed: 17582783
J Immunother Cancer. 2019 Nov 6;7(1):288
pubmed: 31694706
Cancer J. 2018 Jan/Feb;24(1):47-53
pubmed: 29360728
Sci Transl Med. 2019 Jul 3;11(499):
pubmed: 31270275
J Biol Chem. 2010 Jul 30;285(31):23889-98
pubmed: 20472553
Trends Immunol. 2019 Aug;40(8):735-747
pubmed: 31255505
Immunity. 2013 Apr 18;38(4):729-41
pubmed: 23562161
Br J Cancer. 2008 Dec 2;99(11):1808-15
pubmed: 19034280
Front Immunol. 2019 Feb 08;10:173
pubmed: 30800127
J Exp Med. 1995 Aug 1;182(2):459-65
pubmed: 7543139
Front Immunol. 2018 Jul 16;9:1643
pubmed: 30061897
Med Sci Monit. 2018 Jan 25;24:486-502
pubmed: 29368698
Eur J Immunol. 2018 Jul;48(7):1164-1173
pubmed: 29676785
Nat Rev Mol Cell Biol. 2010 Feb;11(2):103-12
pubmed: 20094051
Annu Rev Med. 2015;66:97-110
pubmed: 25341012
J Exp Med. 2020 Aug 3;217(8):
pubmed: 32453421
Cell Metab. 2017 Jun 6;25(6):1213-1215
pubmed: 28591629
J Biol Chem. 2004 Oct 1;279(40):42008-17
pubmed: 15284245
Immunity. 2018 Jan 16;48(1):91-106.e6
pubmed: 29343444
Cell Rep. 2019 Dec 3;29(10):3293-3302.e3
pubmed: 31801090
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Nat Immunol. 2018 Feb;19(2):108-119
pubmed: 29348500
Mol Cancer Ther. 2004 Dec;3(12):1651-8
pubmed: 15634659
Clin Cancer Res. 2020 Jul 1;26(13):3091-3099
pubmed: 32071116
Cancer Res. 2006 Jul 15;66(14):7261-9
pubmed: 16849575

Auteurs

Mehdi Chaib (M)

Department of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA.

Laura M Sipe (LM)

Department of Medicine, Division of Hematology and Oncology, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA.

Johnathan R Yarbro (JR)

Department of Medicine, Division of Hematology and Oncology, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA.

Margaret S Bohm (MS)

Department of Microbiology, Immunology, and Biochemistry, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA.

Brittany R Counts (BR)

Division of Regenerative and Rehabilitation Sciences, College of Health Professions, UTHSC Memphis, USA.

Ubaid Tanveer (U)

Department of Medicine, Division of Hematology and Oncology, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA.

Ajeeth K Pingili (AK)

Department of Medicine, Division of Hematology and Oncology, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA.

Deidre Daria (D)

Office of Vice Chancellor for Research, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA.

Tony N Marion (TN)

Department of Microbiology, Immunology, and Biochemistry, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA; Office of Vice Chancellor for Research, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA.

James A Carson (JA)

Division of Regenerative and Rehabilitation Sciences, College of Health Professions, UTHSC Memphis, USA; UTHSC Center for Cancer Research, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA.

Paul G Thomas (PG)

Department of Microbiology, Immunology, and Biochemistry, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA; Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA; UTHSC Center for Cancer Research, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA.

Liza Makowski (L)

Department of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA; Department of Medicine, Division of Hematology and Oncology, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA; Department of Microbiology, Immunology, and Biochemistry, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA; UTHSC Center for Cancer Research, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA. Electronic address: liza.makowski@uthsc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › PKC agonism restricts innate immune...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › PKC agonism restricts innate immune...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes B › Antigènes CD40 › PKC agonism restricts innate immune...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › PKC agonism restricts innate immune...
questionsmedicales.fr › Phénomènes du système immunitaire › Activation des lymphocytes › Cross-priming › PKC agonism restricts innate immune...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Système phagocytaire mononucléé › Cellules dendritiques › PKC agonism restricts innate immune...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › PKC agonism restricts innate immune...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité innée › PKC agonism restricts innate immune...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › PKC agonism restricts innate immune...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › PKC agonism restricts innate immune...